Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
Aldeyra Therapeutics (Nasdaq: ALDX), a clinical-stage biotech firm focused on immune-mediated and metabolic diseases, announced that CEO Todd C. Brady will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event, featuring a discussion with Jefferies' SVP Kelly Shi, is scheduled for 3:30 p.m. ET on June 5, 2024. The company specializes in developing RASP modulators like reproxalap and ADX-2191 for treating conditions such as dry eye disease and retinitis pigmentosa. Webcast details are available on Aldeyra's website, with the session archived for 90 days.
- Aldeyra's CEO, Todd C. Brady, will be participating in a prominent event, increasing visibility.
- Participation in the Jefferies Global Healthcare Conference could attract potential investors.
- Aldeyra is focused on innovative therapies for immune-mediated and metabolic diseases.
- The company's late-stage product candidates include reproxalap and ADX-2191, targeting dry eye disease and retinitis pigmentosa.
- No specific financial updates or revenue figures were mentioned in the press release.
- There are inherent risks associated with clinical-stage biotech companies, including the success rate of clinical trials.
- The announcement does not include any new clinical data or breakthroughs, which might be anticipated by investors.
- Potential market volatility around the time of the conference if the discussion does not meet investor expectations.
Dr. Brady’s conversation with Kelly Shi, Ph.D., Senior Vice President, Biotechnology Equity Research at Jefferies, is scheduled to begin at 3:30 p.m. ET Wednesday, June 5, 2024. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the fireside chat, the webcast will be archived for 90 days.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the potential treatment of immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529826900/en/
Investor & Media Contact:
David Burke
Tel: (917) 618-2651
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
FAQ
What is the date and time of Aldeyra Therapeutics' participation in the Jefferies Global Healthcare Conference?
Who will represent Aldeyra Therapeutics at the Jefferies Global Healthcare Conference?
What is Aldeyra Therapeutics developing?
What are the key product candidates of Aldeyra Therapeutics?
How can I watch the Aldeyra Therapeutics fireside chat at the Jefferies Global Healthcare Conference?
